Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

JACC: Heart Failure

Volumn 8, Issue 1, 2020, Pages 57-66

  Li, JingWei ^a,b,c   Woodward, Mark ^c,d,e   Perkovic, Vlado ^c   Figtree, Gemma A ^f,g   Heerspink, Hiddo J L ^c,h   Mahaffey, Kenneth W ⁱ   de Zeeuw, Dick ^h   Vercruysse, Frank ^j   Shaw, Wayne ^k   Matthews, David R ^l   Neal, Bruce ^c,m,n  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

^g University of Sydney   (Australia)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^k JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^l UNIVERSITY OF OXFORD   (United Kingdom)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

canagliflozin; heart failure; mediation analysis; renal outcomes

Indexed keywords

ALBUMIN; BICARBONATE; CANAGLIFLOZIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SERUM ALBUMIN; URATE;

ARTICLE; BICARBONATE BLOOD LEVEL; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; ERYTHROCYTE; HEART FAILURE; HEMATOCRIT; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL SYSTEM PARAMETERS; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; URINARY ALBUMIN CREATININE RATIO; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE FUNCTION; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; VENTRICULAR FUNCTION, LEFT;

EID: 85076595299     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2019.08.004     Document Type: Article

References (32)

1. Zinman, B., Wanner, C., Lachin, J., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
2. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
3. Ferrannini, E., DeFronzo, R.A., Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J 36 (2015), 2288–2296.
4. DeFronzo, R.A., Norton, L., Abdul-Ghani, M., Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 13 (2017), 11–26.
5. Sha, S., Polidori, D., Heise, T., et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab 16 (2014), 1087–1095.
6. Hayes, A.F., Rockwood, N.J., Regression-based statistical mediation and moderation analysis in clinical research: observations, recommendations, and implementation. Behav Res Ther 98 (2017), 39–57.
7. VanderWeele, T.J., Vansteelandt, S., Mediation analysis with multiple mediators. Epidemiol Methods 2 (2014), 95–115.
8. Inzucchi, S.E., Zinman, B., Fitchett, D., et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41 (2018), 356–363.
9. Neal, B., Perkovic, V., de Zeeuw, D., et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—a randomized placebo-controlled trial., 166, 2013, 217–223.
10. Neal, B., Perkovic, V., Matthews, D.R., et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab 19 (2017), 387–393.
11. Kazdin, A.E., Mediators and mechanisms of change in psychotherapy research. Annu Rev Clin Psychol 3 (2007), 1–27.
12. Powell, T.M., Bagnell, M.E., Your “survival” guide to using time-dependent covariates. Proceedings of the SAS Global Forum. 2012:22–25. Available at: https://support.sas.com/resources/papers/proceedings12/168-2012.pdf. (Accessed 26 August 2019)
13. Hafeman, D.M., “Proportion explained”: a causal interpretation for standard measures of indirect effect?. Am J Epidemiol 170 (2009), 1443–1448.
14. Valeri, L., VanderWeele, T.J., SAS macro for causal mediation analysis with survival data. Epidemiology 26 (2015), e23–e24.
15. Yu, Q., Wu, X., Li, B., Scribner, R.A., Multiple mediation analysis with survival outcomes: with an application to explore racial disparity in breast cancer survival. Stat Med 38 (2019), 398–412.
16. Packer, M., Anker, S.D., Butler, J., Filippatos, G., Zannad, F., Effects of sodium-glucose co-transporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2 (2017), 1025–1029.
17. Turbull, F., Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectiviely-designed overviews of randomised trials. Lancet 362 (2003), 1527–1535.
18. Leiter, L., Forst, T., Polidori, D., Balis, D., Xie, J., Sha, S., Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 42 (2016), 25–32.
19. Promrat, K., Kleiner, D.E., Niemeier, H.M., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51 (2010), 121–129.
20. Sano, M., Takei, M., Shiraishi, Y., Suzuki, Y., Increased hematocrit during sodium-glucose co-transporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res 8 (2016), 844–847.
21. Lambers Heerspink, H.J., De Zeeuw, D., Wie, L., Leslie, B., List, J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15 (2013), 853–862.
22. Mudaliar, S., Alloju, S., Henry, R.R., Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 39 (2016), 1115–1122.
23. van Bommel, E.J.M., Muskiet, M.H.A., Tonneijck, L., Kramer, M.H.H., Nieuwdorp, M., van Raalte, D.H., SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome. Clin J Am Soc Nephrol 12 (2017), 700–710.
24. Solini, A., Giannini, L., Seghieri, M., et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol, 16, 2017, 138.
25. Yukihiro, C., Yoshishige, S., Soichi, S., et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 35 (2014), 391–404.
26. Kanbay, M., Jensen, T., Solak, Y., et al. Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Intern Med 29 (2016), 3–8.
27. Daniele, G., Xiong, J., Solis-Herrera, C., et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care 39 (2016), 2036–2041.
28. Aubert, G., Martin, O.J., Horton, J.L., et al. The failing heart relies on ketone bodies as a fuel. Circulation 133 (2016), 698–705.
29. Petrykiv, S., Sjostrom, C.D., Greasley, P.J., Xu, J., Persson, F., Heerspink, H.J.L., Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol 12 (2017), 751–759.
30. Scheen, A., Esser, N., Paquot, N., Antidiabetic agents: potential anti-inflammatory activity beyond glucose control. Diabetes Metab 41 (2015), 183–194.
31. Kusaka, H., Koibuchi, N., Hasegawa, Y., Ogawa, H., Kim-Mitsuyama, S., Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol, 15, 2016, 157.
32. Chilton, R., Tikkanen, I., Cannon, C.P., et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17 (2015), 1180–1193.